ATE169409T1 - Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung - Google Patents

Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung

Info

Publication number
ATE169409T1
ATE169409T1 AT95923835T AT95923835T ATE169409T1 AT E169409 T1 ATE169409 T1 AT E169409T1 AT 95923835 T AT95923835 T AT 95923835T AT 95923835 T AT95923835 T AT 95923835T AT E169409 T1 ATE169409 T1 AT E169409T1
Authority
AT
Austria
Prior art keywords
positive
cell
release
antibody
cell suspension
Prior art date
Application number
AT95923835T
Other languages
English (en)
Inventor
Janet Tseng-Law
Joan A Kobori
Fahad A Al-Abdaly
Roy Guillermo
Sam L Helgerson
Robert J Deans
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of ATE169409T1 publication Critical patent/ATE169409T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT95923835T 1994-06-14 1995-06-13 Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung ATE169409T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25942794A 1994-06-14 1994-06-14

Publications (1)

Publication Number Publication Date
ATE169409T1 true ATE169409T1 (de) 1998-08-15

Family

ID=22984902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95923835T ATE169409T1 (de) 1994-06-14 1995-06-13 Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung

Country Status (10)

Country Link
US (2) US6017719A (de)
EP (1) EP0765478B1 (de)
JP (1) JP2849630B2 (de)
AT (1) ATE169409T1 (de)
AU (1) AU697627B2 (de)
CA (1) CA2192455C (de)
DE (1) DE69503903T2 (de)
DK (1) DK0765478T3 (de)
ES (1) ES2121400T3 (de)
WO (1) WO1995034817A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2593192A (en) 1992-09-14 1994-04-12 Oystein Fodstad Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
US6066516A (en) * 1995-06-26 2000-05-23 Seiko Epson Corporation Method for forming crystalline semiconductor layers, a method for fabricating thin film transistors, and method for fabricating solar cells and active matrix liquid crystal devices
NO961031D0 (no) * 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
WO1997044666A1 (en) * 1996-05-17 1997-11-27 Cytovax Biotechnologies Inc. Immunological methods of component selection and recovery
CA2278208C (en) * 1997-01-24 2011-09-20 Asahi Medical Co., Ltd. Cell separation method
US7364921B1 (en) * 1999-01-06 2008-04-29 University Of Medicine And Dentistry Of New Jersey Method and apparatus for separating biological materials and other substances
US6379952B1 (en) * 1999-02-01 2002-04-30 3M Innovative Properties Company Method for cell selection utilizing azlactone-functional supports
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
DE10014708A1 (de) * 2000-03-24 2001-10-31 Walter Schubert Verfahren zur Identifizierung und Anreicherung von zellspezifischen Zielstrukturen
DE10014685B4 (de) * 2000-03-24 2004-07-01 Schubert, Walter, Dr. Verfahren zur Identifizierung von zellspezifischen Zielstrukturen
US20030219445A1 (en) * 2000-05-23 2003-11-27 Nexell Therapeutics, Inc. Reagents for cell selection and methods of use
DE60132221T2 (de) * 2000-05-23 2009-01-02 Baxter Healthcare S.A., Wallisellen Reagenzien zur zellselektion und verfahren zur anwendung
US6576276B1 (en) 2000-10-25 2003-06-10 The Coca-Cola Company CO2-hydrate product and method of manufacture thereof
ES2643582T3 (es) 2001-02-20 2017-11-23 Janssen Pharmaceuticals, Inc. Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP1372721A4 (de) 2001-03-07 2008-04-02 Childrens Medical Center Verfahren zum screening von peptid-display-bibliotheken mit minizellen-display
KR100930139B1 (ko) 2001-12-07 2009-12-07 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
WO2003065358A2 (en) * 2002-01-28 2003-08-07 Burstein Technologies, Inc. Methods and apparatus for logical triggering of an optical bio-disc
AU2003209372B2 (en) * 2002-01-31 2009-02-19 Burstein Technologies, Inc. Method for triggering through disc grooves and related optical analysis discs and system
US20030166138A1 (en) * 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
ITUD20020092A1 (it) * 2002-04-30 2002-07-30 Univ Degli Studi Udine Metodo per l'identificazione e l'isolamento di cellule staminali di un tessuto umano
DK1458853T3 (da) * 2002-05-16 2010-04-06 Absorber Ab Fremgangsmåde til donorspecifik krydsmatchning
US9435799B2 (en) * 2002-07-31 2016-09-06 Janssen Diagnostics, Inc. Methods and reagents for improved selection of biological materials
WO2004014944A1 (ja) * 2002-08-07 2004-02-19 Okayama Prefecture 微生物由来のポリアミノ酸またはその誘導体
US20050042623A1 (en) * 2002-10-30 2005-02-24 Dana Ault-Riche Systems for capture and analysis of biological particles and methods using the systems
MXPA05009044A (es) 2003-02-20 2006-03-17 Macropore Biosurgery Inc Metodos para utilizar celulas derivadas de tejido adiposo en el tratamiento de condiciones cardiovasculares.
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
IL157086A0 (en) * 2003-07-24 2004-02-08 Guy Patchornik Multivalent ligand complexes
US7996825B2 (en) * 2003-10-31 2011-08-09 Hewlett-Packard Development Company, L.P. Cross-file inlining by using summaries and global worklist
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics
US9790539B2 (en) * 2004-06-30 2017-10-17 Russell Biotech, Inc. Methods and reagents for improved selection of biological molecules
US20100111980A1 (en) * 2004-12-10 2010-05-06 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Binding partners of antibodies specific for dendritic cell antigens
US20080206276A1 (en) 2005-07-08 2008-08-28 Michael Otto Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
EP1951864B1 (de) 2005-11-07 2014-05-07 Amorcyte, Inc. Zusammensetzungen und verfahren zur reparatur von gefässverletzungen
US20100129837A1 (en) * 2006-11-22 2010-05-27 Mach Patrick A Methods of capturing bacterial whole cells and methods of analyzing samples for bacteria
EP2114992A2 (de) * 2007-01-09 2009-11-11 Yissum Research Development Company, of The Hebrew University of Jerusalem Antibakterielle peptide und verfahren zur behandlung von krankheiten unter deren verwendung
WO2009047003A1 (en) * 2007-10-12 2009-04-16 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Method and kit for rapid isolation of human foxp3+ treg cells
ATE493491T1 (de) * 2007-10-12 2011-01-15 Max Delbrueck Centrum Verfahren und kit zur schnellen isolierung humaner foxp3-treg-zellen
US8399249B2 (en) 2008-02-21 2013-03-19 Baxter International Inc. Procedure for the generation of a high producer cell line for the expression of a recombinant anti-CD34 antibody
US20100028311A1 (en) * 2008-07-09 2010-02-04 Baxter International Inc. Using of scaffold comprising fibrin for delivery of stem cells
JP5638747B2 (ja) * 2008-08-20 2014-12-10 株式会社日立製作所 がん腫の遺伝子診断のための細胞回収及び単離方法並びにキット
CN102186968A (zh) * 2008-10-17 2011-09-14 巴克斯特国际公司 从脂肪组织获得细胞群的方法
ES2610241T3 (es) 2009-10-23 2017-04-26 Amorcyte, Inc. Composiciones y usos para el tratamiento de lesiones miocárdicas progresivas debidas a una insuficiencia vascular
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
EP2718424B1 (de) 2011-05-17 2018-10-03 Lonza Walkersville, Inc. Durchgangs- und entnahmeformulierung und verfahren für menschliche pluripotente stammzellen
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
US9533010B2 (en) 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
JP2015508101A (ja) 2012-02-21 2015-03-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｃｄ３４＋細胞を含む薬学的組成物
EP2819698A4 (de) * 2012-02-28 2015-11-11 Univ Ben Gurion Kombinationstherapie aus alpha-1-antitrypsin und einer temporalen t-zellen-abreicherung zur hemmung einer transplantatabstossung
US20190204312A1 (en) * 2016-09-16 2019-07-04 Technische Universität München Magnetic particle-binding peptides
WO2019013148A1 (ja) * 2017-07-11 2019-01-17 国立大学法人富山大学 細胞の選択的分離用又は細胞培養用ポリマーにより被覆された基体
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US12011459B2 (en) * 2019-06-06 2024-06-18 Immatics US, Inc. Methods for manufacturing T cells by direct sorting and compositions thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP4000596A1 (de) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptid und zusammensetzungen mit tetrapeptiden
EP4000595A1 (de) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptid und zusammensetzungen mit tetrapeptiden
WO2023141297A2 (en) * 2022-01-21 2023-07-27 Marengo Therapeutics, Inc. Multifunctional molecules comprising g6b binder and/or cd34 binder and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
IL76234A0 (en) * 1985-08-28 1986-01-31 Yeda Res & Dev New biotinylation reagents
US5225353A (en) * 1986-01-30 1993-07-06 Fred Hutchinson Cancer Research Center Method for immunoselection of cells using avidin and biotin
US5215927A (en) * 1986-01-30 1993-06-01 Fred Hutchinson Cancer Research Center Method for immunoselection of cells using avidin and biotin
US4709037A (en) * 1987-02-17 1987-11-24 Hoechst Celanese Corporation Biotinylating agents
US4798795A (en) * 1987-02-17 1989-01-17 Hoechst Celanese Corporation Biotinylating agents
PT90657B (pt) * 1988-05-27 1995-03-01 Ortho Pharma Corp Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
US5316943A (en) * 1988-06-14 1994-05-31 Kidman Gene E Racemic conversion of using a transaminase
US5536475A (en) * 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5081030A (en) * 1989-04-25 1992-01-14 The Johns Hopkins University Release of cells from affinity matrices
GB8916859D0 (en) * 1989-07-24 1989-09-06 Dynal As Hapten linking
EP0563212A1 (de) * 1990-11-23 1993-10-06 Immunodynamics, Inc. Synthetische immunoaktive peptide mit immunmodulierenden und therapeutischen wirkungen
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
DE69220397T2 (de) * 1991-03-13 1997-10-02 Morinaga Milk Industry Co Ltd Antimikrobielles Peptid und antimikrobieller Wirkstoff
WO1993014781A1 (en) * 1992-01-24 1993-08-05 The Regents Of The University Of California Novel peptides and method for altering the activity of allosteric proteins
WO1993016715A1 (en) * 1992-02-24 1993-09-02 New England Medical Center Hospitals, Inc. Fsf-1 and the early detection of fibrosis
WO1994002016A1 (en) * 1992-07-28 1994-02-03 Steven Kessler Methods for positive immunoselection of stem cells
FR2694938B1 (fr) * 1992-08-10 1996-11-15 Zagury Jean Francois Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
JP3401005B2 (ja) * 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
EP0717848A1 (de) * 1993-09-08 1996-06-26 Baxter International Inc. Mit biotinanaloga konjugierte antikörper für die positive zellselektion und zellfreisetzung
US5525503A (en) * 1993-09-28 1996-06-11 Dana-Farber Cancer Institute, Inc. Signal transduction via CD28
US5409813A (en) * 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use

Also Published As

Publication number Publication date
AU697627B2 (en) 1998-10-15
WO1995034817A1 (en) 1995-12-21
US6017719A (en) 2000-01-25
CA2192455A1 (en) 1995-12-21
CA2192455C (en) 2007-11-20
EP0765478A1 (de) 1997-04-02
US5968753A (en) 1999-10-19
JP2849630B2 (ja) 1999-01-20
EP0765478B1 (de) 1998-08-05
ES2121400T3 (es) 1998-11-16
DK0765478T3 (da) 1999-05-03
DE69503903T2 (de) 1999-03-25
JPH09508534A (ja) 1997-09-02
AU2826195A (en) 1996-01-05
DE69503903D1 (de) 1998-09-10

Similar Documents

Publication Publication Date Title
ATE169409T1 (de) Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung
DE69230146D1 (de) Monoklonale antikörper gegen putative hcv-e2/ns1-proteine und verfahren zu ihrer verwendung
WO1999006834A3 (en) Methods for identifying ligand specific binding molecules
CA2215042A1 (en) Assay reagents and devices
EP0930366A3 (de) Bindungsdomänen des Serrate-proteins
WO1995018381A1 (en) Immunoassays for prostate specific antigen
WO1998027114A3 (en) Mammalian cell surface antigens; related reagents
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
EP2186884A3 (de) Monoklonale Antikörpergegen HCV Kernantigen
HK1048477A1 (zh) 卵巢的癌細胞及骨髓癌細胞使糖蛋白浮現，它的抗體及其使用
Kourilov et al. Magnetic-bead enzyme-linked immunosorbent assay verifies adsorption of ligand and epitope accessibility
EP1114864A3 (de) Oberflächenantigene aus Säugern mit Strukturmotifen die charakteristisch für Mitglieder der TNF Liganden Familie sind
IE883062L (en) Monoclonal antibodies
EP0227440A3 (de) Immunotestverfahren für Kreatine-Kinase-MB unter Verwendung von gebundenen und löslichen Antikörpern
IL154000A (en) A method that uses antibodies to diagnose arthritis
ATE426158T1 (de) Mikrofluidisches extraktionsverfahren
CA2221682A1 (en) Method of preparing a monoclonal antibody, monoclonal antibody, a pharmaceutical composition and a diagnostic reagent
KR920006005A (ko) 인체 IgE에 대한 모노클론 항체
CA2411392A1 (en) Tetrameric antibody complexes for blocking non-specific binding of antigens
GB2171999A (en) Antibodies
Steinitz et al. An improved method to create nitrocellulose particles suitable for the immobilization of antigen and antibody
CA2095735A1 (en) Monoclonal antibodies to hepatitis c virus and method for using same
CA2112667A1 (en) Monoclonal antibodies to putative hcv ns5 proteins and methods for using same
DE60029570D1 (de) Verfahren zur isolierung der cd8+-zellen, und entsprechende hybridomazellen, antikörper und polypeptide
NZ335545A (en) Monoclonal dendritic cell (DC)-specific antibodies that binds to DC activated antigen CMRF-56

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification